Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer

Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer

A good response to neoadjuvant chemotherapy (NACT) is strongly associated with a higher curative resection rate and favorable outcomes for patients with gastric cancer (GC). We examined the utility of serial circulating tumor DNA (ctDNA) testing for monitoring NACT response and prognosis in stage II...

Full description

Bibliographic Details
Main Authors: Meng Zhang, Heli Yang, Tao Fu, Meizhu Meng, Yi Feng, Changda Qu, Zhongwu Li, Xiaofang Xing, Wenmei Li, Meiying Ye, Sisi Li, Zhaode Bu, Shuqin Jia
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Molecular Oncology
Subjects:
circulating tumor DNA
gastric cancer
neoadjuvant chemotherapy
prognosis
response
Online Access:https://doi.org/10.1002/1878-0261.13481

Internet

https://doi.org/10.1002/1878-0261.13481

Similar Items